Point‐of‐care testing in haemostasis

British Journal of Haematology - Tập 150 Số 5 - Trang 501-514 - 2010
David J. Perry1, David Fitzmaurice2, Steve Kitchen3, Ian Mackie4, Susan Mallett5
1Department of Haematology, Addenbrooke's Hospital, Cambridge
2Department of Primary Care Clinical Sciences, Clinical Sciences Building, The University of Birmingham, Birmingham
3UK National External Quality Assessment Scheme (Blood Coagulation), Rutledge Mews, Southbourne Road, Sheffield
4Haemostasis Research Unit, Department of Haematology, University College London, London
5Department of Anaesthesia, Royal Free Hospital, London, UK

Tóm tắt

SummaryPoint‐of‐care testing (POCT) in haematology has seen a significant increase in both the spectrum of tests available and the number of tests performed annually. POCT is frequently undertaken with the belief that this will reduce the turnaround time for results and so improve patient care. The most obvious example of POCT in haemostasis is the out‐of‐hospital monitoring of the International Normalized Ratio in patients receiving a vitamin K antagonist, such as warfarin. Other areas include the use of the Activated Clotting Time to monitor anticoagulation for patients on cardio‐pulmonary bypass, platelet function testing to identify patients with apparent aspirin or clopidogrel resistance and thrombelastography to guide blood product replacement during cardiac and hepatic surgery. In contrast to laboratory testing, POCT is frequently undertaken by untrained or semi‐trained individuals and in many cases is not subject to the same strict quality control programmes that exist in the central laboratory. Although external quality assessment programmes do exist for some POCT assays these are still relatively few. The use of POCT in haematology, particularly in the field of haemostasis, is likely to expand and it is important that systems are in place to ensure that the generated results are accurate and precise.

Từ khóa


Tài liệu tham khảo

10.1097/00000542-200610000-00011

10.1111/j.1540-8191.2009.00840.x

10.1097/00000542-200111000-00021

10.1111/j.1751-553X.2009.01214.x

10.1016/S0002-8703(99)70460-6

10.1097/00000539-200005000-00015

10.1080/0953710031000118849

10.1016/j.amjcard.2006.09.011

10.1111/j.1365-2141.2008.07274.x

10.1097/00000539-200301000-00011

10.1016/j.lab.2005.12.007

10.1016/j.trsl.2009.04.001

10.1016/j.jclinane.2003.03.004

10.1016/j.jtcvs.2004.02.019

10.1016/j.jacc.2003.12.034

10.1309/VRXF-C68K-PMU9-QDKW

10.1097/00000539-199508000-00011

10.1053/j.jvca.2006.01.016

10.1016/S0049-3848(99)00034-1

10.1016/j.lab.2004.01.011

10.1097/00000658-198101000-00017

10.1160/TH05-12-0826

Despotis G.J., 1994, Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti‐Xa heparin concentration in patients having cardiac operations, Journal of Thoracic and Cardiovascular Surgery, 108, 1076, 10.1016/S0022-5223(94)70150-4

10.1097/00000542-199612000-00012

10.1016/S0022-5223(97)70380-5

10.1046/j.1525-1594.1998.05078.x

10.1055/s-0029-1220322

10.1056/NEJMoa0802395

10.1007/BF03020384

10.1093/bja/89.5.715

10.1093/ndt/gfh203

10.1111/j.1365-2141.2005.05394.x

10.1136/jcp.2008.059634

10.1136/bmj.b2990

Gosselin R., 2000, A comparison of point‐of‐care instruments designed for monitoring oral anticoagulation with standard laboratory methods, Thrombosis and Haemostasis, 83, 698, 10.1055/s-0037-1613895

10.1016/0003-4975(94)91103-7

10.1159/000190134

10.1093/bja/78.2.175

10.1111/j.1365-2141.2005.05511.x

10.1055/s-0029-1220323

10.1016/j.thromres.2006.11.012

10.1001/jama.1966.03100180108036

10.1055/s-2007-971814

10.1373/clinchem.2004.031765

10.1067/mhj.2001.117317

10.1532/HSF98.20041122

10.1080/09537100600935259

Hunt B.J., 1992, Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass, Journal of Thoracic and Cardiovascular Surgery, 104, 211, 10.1016/S0022-5223(19)34860-3

10.1080/00365510600672783

Jaryno S., 2002, Validation of a new whole blood coagulation monitoring system, The Journal of Extra-corporeal Technology, 34, 271, 10.1051/ject/2002344271

Jones K., 2004, The in vitro effects of aprotinin on twelve different ACT tests, The Journal of Extra-corporeal Technology, 36, 51, 10.1051/ject/200436151

De Jong M.A., 1999, High dose thrombin time versus the activated clotting time during cardiopulmonary bypass, The Journal of Extra-corporeal Technology, 31, 76, 10.1051/ject/199931276

10.1055/s-2007-994036

Kang Y., 1995, Thromboelastography in liver transplantation, Seminars in Thrombosis and Hemostasis, 21, 34

10.1002/lt.500030621

10.1016/j.ejcts.2003.11.037

10.1097/00005373-199704000-00023

10.1046/j.1365-2141.2003.04723.x

10.1097/00000539-199909000-00007

10.1055/s-0038-1648883

Kitchen D.P., 2009, Establishment of an external quality assessment programme for users of activated clotting time, Journal of Thrombosis and Haemostasis, 7, PP‐MO‐116

Lasne D., 2000, A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft, Thrombosis and Haemostasis, 84, 794, 10.1055/s-0037-1614118

10.1002/ccd.10683

10.1016/j.athoracsur.2005.03.074

10.1093/bja/aen083

10.1097/00000539-200103000-00005

10.1016/S0049-3848(02)00340-7

10.1016/S0735-1097(02)02762-6

10.1213/01.ANE.0000155290.86795.12

10.1007/s00134-006-0220-8

MHRA(2010)Device Bulletin Management and Use of IVD Point of Care Test Devices. In:http://www.mhra.gov.uk/Publications/Safetyguidance/DeviceBulletins/CON071082.

10.1016/j.amjcard.2006.09.008

10.1097/00000542-199207000-00007

10.1016/S1053-0770(97)90247-0

10.1097/01.mbc.0000198047.35010.77

10.1016/1053-0770(93)90160-M

10.1016/S1053-0770(05)80087-4

10.1097/00001721-200404000-00002

10.1097/00000542-200307000-00012

10.1067/mva.2002.122027

10.1097/TA.0b013e318160772d

10.1186/1477-9560-1-1

10.1067/mtc.2001.114344

10.1002/ccd.1810320112

10.1592/phco.22.9.677.34060

10.1510/icvts.2005.115154

10.1093/bja/86.4.575

10.1111/j.1538-7836.2007.02319.x

10.1046/j.1423-0410.2003.00304.x

10.1023/A:1012923505198

10.1177/108925320500900105

10.1097/00000539-199902000-00016

10.1097/00000542-199908000-00008

10.1007/BF03022248

10.1097/00001721-200103000-00001

10.1309/N7RA-D6XN-9EQX-ABJ9

10.1080/00365510600684580

10.1097/00006247-200505000-00010

Spiess B.D., 1996, Coagulation monitoring in the perioperative period, Acta Anaesthesiologica Scandinavica. Supplementum, 109, 77

10.1007/BF00770880

10.1016/S1053-0770(05)80189-2

10.1080/09537100600757521

10.1592/phco.19.6.383.31039

10.1016/j.thromres.2004.01.009

10.1016/1053-0770(94)90052-3

10.1097/00000542-199212000-00006

10.1213/00000539-199407000-00003

10.1023/A:1021298103264

10.1016/j.hlc.2008.08.016

10.1177/107602960501100202

10.1097/00003246-200112000-00006

10.1016/S0002-8703(98)70133-4

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 150 Số 5

501-514

Thông tin tác giả